Gene · 27329
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reduction. | Trends Cardiovasc Med | 2025 | 40664304 | PubTator, text mining | PubMed |
| Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors. | Am J Cardiovasc Drugs | 2025 | 40652105 | PubTator, text mining | PubMed |
| Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial. | Nat Med | 2025 | 40640392 | PubTator, text mining | PubMed |
| ANGPTL3 orchestrates hepatic fructose sensing and metabolism. | Cell Rep | 2025 | 40638391 | PubTator, text mining | PubMed |
| SHR-1918, A Monoclonal Antibody Against Angiopoietin-Like 3, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study. | Clin Pharmacokinet | 2025 | 40576753 | PubTator, text mining | PubMed |
| RNA Interference-Mediated ANGPTL3 Inhibition: The Emerging Therapeutic Potential of Zodasiran in Lipid Management. | Cardiol Rev | 2025 | 40576350 | PubTator, text mining | PubMed |
| Changes After Leptin Administration in Partial Lipodystrophy and Factors Associated With Hepatic and Metabolic Response. | J Endocr Soc | 2025 | 40520449 | PubTator, text mining | PubMed |
| siRNAs targeting ANGPTL3 for mixed dyslipidemia. | Med | 2025 | 40516518 | PubTator, text mining | PubMed |
| Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention. | J Natl Cancer Inst | 2025 | 40511612 | PubTator, text mining | PubMed |
| Circulating protein biomarkers and their association with vulnerable plaque characteristics - a PROSPECT II substudy. | Int J Cardiol Cardiovasc Risk Prev | 2025 | 40503438 | PubTator, text mining | PubMed |
| A multivariable cis-Mendelian randomization method robust to weak instrument bias and horizontal pleiotropy bias. | Brief Bioinform | 2025 | 40471990 | PubTator, text mining | PubMed |
| ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis. | J Atheroscler Thromb | 2025 | 40467521 | PubTator, text mining | PubMed |
| Effect of complete, lifelong ANGPTL3 deficiency on triglyceride-rich lipoprotein kinetics. | Cell Rep Med | 2025 | 40446802 | PubTator, text mining | PubMed |
| Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective-Brief Report. | Arterioscler Thromb Vasc Biol | 2025 | 40438928 | PubTator, text mining | PubMed |
| Bridging systemic metabolic dysfunction and Alzheimer's disease: the liver interface. | Mol Neurodegener | 2025 | 40437610 | PubTator, text mining | PubMed |
| Unveiling the PGAM5-ANGPTL3 Axis: Implications for Atherosclerosis Progression and Therapy. | JACC Basic Transl Sci | 2025 | 40436528 | PubTator, text mining | PubMed |
| Phosphoglycerate Mutase 5 Is Important Mediator for Instigating Arterial Lipid Accumulation and Aggravating Atherosclerosis. | JACC Basic Transl Sci | 2025 | 40436527 | PubTator, text mining | PubMed |
| Mediating Role of the ANGPTL3/TFPI Protein Ratio in Regulating T-Cell Surface Glycoprotein CD5 Levels on Knee Osteoarthritis (KOA): A Mendelian Randomization Study. | Int J Mol Sci | 2025 | 40429617 | PubTator, text mining | PubMed |
| ANGPTL3 vital role in different kidney diseases. Current knowledge and future perspectives. | Biomed Pharmacother | 2025 | 40412362 | PubTator, text mining | PubMed |
| Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C. | Atherosclerosis | 2025 | 40393255 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/27329/papers?page=11